Business
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
– Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, ...
About this update from Bright Minds Biosciences Inc.
[{"type":"text","content":"Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research\n\n\n\n – Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in epilepsy drug development and research to support Company’s clinical focus on epilepsy –\n \n\n VANCOUVER, British Columbia, March 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“\n \n Bright Minds\n \n ” or the “\n \n Company\n \n ”), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced the expansion of its Scientific Advisory Board (SAB) to include five distinguished experts in epilepsy research:\n \n\n\n Dennis Dlugos, MD, MSCE\n \n\n Jacqueline French, MD\n \n\n Terrence O'Brien, MD\n \n\n Jo Sourbron, MD, PhD, MPharm\n \n\n Joseph Sullivan, MD\n \n\n\n\n “The addition of these five esteemed scientists to our SAB reflects our deepening clinical focus on epilepsy. Together with our current SAB members, their expertise will be invaluable as we continue our Phase 2 BREAKTHROUGH study of BMB-101 in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE). Their cumulative experience advising on clinical trials across numerous epilepsy and related brain diseases, both in pediatric and adult patient populations, will help shape our trajectory as we seek to advance our pipeline of product candidates,” said Stephen Collins, Chief Medical Officer of Bright Minds Biosciences.\n \n\n “We are fortunate to welcome these accomplished and highly respected researchers to the Bright Minds team at this exciting juncture. As we advance our clinical programs through the regulatory process, their perspectives and real-world experience will provide important guidance around our development efforts. Epilepsy affects more than 70 million people worldwide, and we are committed to pursuing therapies that reduce seizure frequency and improve the quality of life for patients with drug-resistant epilepsy,” said Ian McDonald, CEO and Co-founder of Bright Minds Biosciences.\n \n\n\n Denn...